Bronnen:
Stellbrink H, et al. Phase III randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) versus dolutegravir (DTG) + F/TAF in treatmentnaïve HIV-1 positive adults: Week 96. Abstract O211. HIV/Drug Therapy Glasgow 2018.
Stellbrink H, et al. Phase III randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) versus dolutegravir (DTG) + F/TAF in treatmentnaïve HIV-1 positive adults: Week 96. Abstract O211. HIV/Drug Therapy Glasgow 2018.